Lightnews — Scholar-powered news

Ryan Elliott @ryanelliott.bsky.social · 22d

📚 This T-cell NHL diagnostic slide has been circulating and provides a nice framework
#medsky #hemesky #hemeonc #lymphoma #pathsky #hemepath #Tcells #cellmarkers #biology #hematology #medicine #pathology #oncology #oncsky #diagnostics #meded

2

Reposted by Ryan Elliott

OncLive @onclive.bsky.social · 22d

Final CAPTIVATE Analysis Data Support Frontline Fixed-Duration Ibrutinib Plus Venetoclax in CLL/SLL
#CLL #Hematology
www.onclive.com/view/final-c...

Final CAPTIVATE Analysis Data Support Frontline Fixed-Duration Ibrutinib Plus Venetoclax in CLL/SLL | OncLive

Paolo Ghia, MD, PhD, details the final analysis of the phase 2 CAPTIVATE study evaluating frontline ibrutinib/venetoclax in patients with CLL.

www.onclive.com

1

Ryan Elliott @ryanelliott.bsky.social · Sep 8

All signed up for the 2025 ASH Annual Meeting. Looking forward to it! #hemesky #ASH25

American Society of Hematology @ash.hematology.org · Jul 23

Open for members
Secure your top hotel pick
Don’t wait! Register 👇

Claim your spot now: https://bit.ly/46VqNXj #ASH25 #ASHaiku

2

Ryan Elliott @ryanelliott.bsky.social · Sep 8

🩸 ISTH DIC score (overt ≥ 5)
Plt <50=2; 50–100=1
PT >6s=2; 3–6s=1
Fibrinogen <1.0g/L=1
D-dimer: >3× ULN=3; 1–3× ULN=2; none=0
#hemesky #medsky #coag #benignheme

Reposted by Ryan Elliott

Thrombosis Canada @thrombosiscan.bsky.social · Jul 4

Join us on October 25 for a packed day of thrombosis education for healthcare professionals. Register today at thrombosiscanada.ca/2025Conference

2

Reposted by Ryan Elliott

OncLive @onclive.bsky.social · Sep 6

Mosunetuzumab/Polatuzumab Vedotin Is an Effective Off-the-Shelf Combo in R/R MCL @mdanderson.bsky.social @societyofhemonc.bsky.social #SOHO2025 #lymsm #hematology
www.onclive.com/view/mosunet...

Mosunetuzumab/Polatuzumab Vedotin Is an Effective Off-the-Shelf Combo in R/R MCL

Treatment with mosunetuzumab plus polatuzumab vedotin yielded high response rates and had a manageable safety profile in BTK inhibitor–exposed MCL.

www.onclive.com

1 2

Ryan Elliott @ryanelliott.bsky.social · Sep 6

🩺 Differentiation Syndrome
- complication that can occur during treatment of APL w/ ATRA+ATO

Clinical:
⬆️ WBCs
⬆️ Fever
⬆️ edema/body weight/pulmonary infiltrates

Mgmt:
- high-dose steroids
- cytoreduction
- antipyretics / cxs / abx for FN
- diuresis

#hemesky #hemeonc #medsky #APL #APML #leukemia

Ryan Elliott @ryanelliott.bsky.social · Aug 17

Not hard to tell that I’m currently on thrombosis! Having a good experience with the team here at McMaster. #thrombosis #hemesky #hematology

1

Reposted by Ryan Elliott

BaladoCritique : club de lecture médical @baladocritique.bsky.social · Jul 18

"Updated definition and scoring of disseminated intravascular coagulation in 2025: communication from the ISTH SSC Subcommittee on Disseminated Intravascular Coagulation."
Publié en juillet dans J Thromb Haemost.
#MedSky #DIC
www.sciencedirect.com/science/arti...

Updated definition and scoring of disseminated intravascular coagulation in 2025: communication from the ISTH SSC Subcommittee on Disseminated Intravascular Coagulation

Compelling evidence supports the need to update the 2001 definition and diagnosis of disseminated intravascular coagulation (DIC) to reflect our curre…

www.sciencedirect.com

1

Ryan Elliott @ryanelliott.bsky.social · Aug 17

🩸📖 NEJM 2003: CLOT trial - 676 patients w/ cancer-associated thrombosis (CAT) - Dalteparin vs warfarin.

Dalteparin dose: 200 IU/kg sc daily ×1/12 → 150 IU/kg daily ×5/12 (total 6 months).

Outcome: ↓ recurrent VTE; no ↑ major bleed in the group who received dalteparin.

#hemesky #thrombosis #medsky

1

Ryan Elliott @ryanelliott.bsky.social · Aug 15

🩸Cancer-associated Thrombosis Trials: LMWH more effective than VKAs

CANTHANOX 2002:
Enoxaparin vs VKA

CLOT 2003:
Dalteparin vs VKA

ONCENOX 2006:
Enoxaparin vs VKA

LITE 2006:
Tinzaparin vs VKA

CATCH 2015:
Tinzaparin vs VKA

#thrombosis #clinicalTrials #hemesky #medsky #IMsky #oncology #hemeonc

Ryan Elliott @ryanelliott.bsky.social · Aug 6

CARAVAGGIO 2020 (1,170 pts):

Apixaban vs dalteparin for cancer VTE. Recurrent VTE 5.6 % vs 7.9 % (non-inf). Major bleed 3.8 % vs 4.0 %; no extra GI bleed. Bottom line: apixaban noninferior to dalteparin without increase in major bleeding in cancer-associated VTE. #medsky #hemesky #thrombosis

Ryan Elliott @ryanelliott.bsky.social · Aug 6

Lesson from this past week:

Isolated elevation of anticardiolipin IgM does not meet laboratory criteria for antiphospholipid syndrome! According to EULAR 2023 guidelines below. #medsky #IMsky #rheumsky #hemesky #antiphospholipid #thrombosis

1

Reposted by Ryan Elliott

Blood Journals' Portfolio @bloodjournals.hematology.org · Aug 4

Ven is effective (91% ORR) and well tolerated in octogenarians, but 43% hd treatment holds and 32% prolonged ramp-up. buff.ly/lNgBN1r #hemesky

1 1

Ryan Elliott @ryanelliott.bsky.social · Aug 4

Monoclonal Gammopathy: Paraneoplastic Neuropathy 🧠🩸

AL Amyloidosis: painful + length-dependent + sensory > motor
POEMS: symmetric disabling demyelinating polyneuropathy
DADS-M: distal loss of proprioception + demyelinating + coarse tremor + mild motor weakness

#hemesky #myeloma #medsky #neurosky

1

Reposted by Ryan Elliott

JAMA @jama.com · May 19

Chronic myeloid leukemia is a myeloproliferative neoplasm.

This Review summarizes the epidemiology, diagnosis, and management of chronic myeloid leukemia.

https://ja.ma/4mlR6ez

Figure 1. Pathogenesis of CML and Mechanism of Action of Available BCR::ABL1 TKIs

3 6

Ryan Elliott @ryanelliott.bsky.social · Jun 13

Thanks for the added detail! 🔬

Reposted by Ryan Elliott

Blood Journals' Portfolio @bloodjournals.hematology.org · Jun 2

Unveiling the enigma: circulating flowerlike large B-lymphoma cells in the context of angioimmunoblastic T-cell lymphoma
buff.ly/bbBzTQG #hemesky #lymphoidneoplasia

1 1

Ryan Elliott @ryanelliott.bsky.social · May 5

🔬🩸Hemoglobin development (some fundamentals!)

Embryo
Hb Gower I = ζ2ε2
Hb Gower II = α2ε2
Hb Portland = ζ2γ2

Fetus
HbF = α2γ2

Adult
HbA = α2β2 ~97%
HbA2 = α2δ2 ~2–3%
HbF <1%
#hemesky #medsky #IMsky #benignheme #hemoglobin #pediatrics

1 2

Reposted by Ryan Elliott

OncLive @onclive.bsky.social · Feb 19

JAK Inhibitor–Based Combos and Mutation-Specific Regimens Comprise the Future of Myelofibrosis Management
#MPNsm #hematology #oncology
www.onclive.com/view/jak-inh...

JAK Inhibitor–Based Combos and Mutation-Specific Regimens Comprise the Future of Myelofibrosis Management

Claire Harrison, MD, FRCP, FRCPath, discusses research that may evolve the clinical use of JAK inhibitors and mutation-specific therapies in myelofibrosis.

www.onclive.com

1 5

Reposted by Ryan Elliott

Frak. @frakbuddy.bsky.social · Feb 20

Workin. CML in a 27 Year old. #haematology #hematology

Blood film picture of a patient with CML showing a variety of immature and mature white blood cells

1

Ryan Elliott @ryanelliott.bsky.social · Feb 6

💊 Abatacept

Humanized protein construct from recombinant DNA (CTLA4 + IgG1 Fc) grown in hamster ovary cells.

Selectively binds to CD80/86 on APCs, inhibiting CD80/86-CD28 costimulatory signal essential for full T-cell activation.

#medsky #IMsky #rheumsky #biologics
(Herrero-Beaumont et al., 2012)

1

Reposted by Ryan Elliott

OncLive @onclive.bsky.social · Jan 22

Isatuximab Plus VRd Wins EU Approval for Newly Diagnosed, Transplant-Ineligible Multiple Myeloma
#mmsm #Hematology
www.onclive.com/view/isatuxi...

Isatuximab Plus VRd Wins EU Approval for Newly Diagnosed, Transplant-Ineligible Multiple Myeloma

The EMA’s CHMP has approved isatuximab in combination with VRd for transplant-ineligible patients with newly diagnosed multiple myeloma.

www.onclive.com

2 4

Reposted by Ryan Elliott

HemaSphere Journal @hemasphere-journal.bsky.social · Jan 23

This recently published study highlights the prognostic significance of high-risk cytogenetic abnormalities in multiple myeloma. Genetic alterations like t(4;14), del(17p), and +1q are linked to poorer prognosis and shorter survival #MM #hematology 👉https://bit.ly/3PzY1BT

1 7

Ryan Elliott @ryanelliott.bsky.social · Jan 24

This looks awesome! 🔬🤩

1 1